Zoetis Class A (ZTS) closed at $82.32 on November 9, 2026, up 3.7% from the previous close, on volume of 5,174,447 shares (30-day average 4,335,504).
Data as of November 9, 2026.
| # | Date | Strategy | Legs | Contracts |
|---|---|---|---|---|
| 1 | Nov 2, 2026 | Condor With Calls (Skip Strike) | 19-Mar-2775 : 85 : 95 : 100 C | 2,792 |
| 2-3 | The next 2 largest trades are for Premium members. Start a 7-day free trial | |||
Ranked by contracts: multi-leg trades of 200 or more contracts on one day, through Nov 9, 2026. See the 10 largest for 30, 60 and 90 days
Zoetis to Participate in the Jefferies Global Healthcare Conference in London
Business Wire (Tue, 10-Nov 7:30 AM ET)
Analysts’ Opinions Are Mixed on These NA Stocks: Strategy (MSTR), Zoetis (ZTS) and Mosaic Co (MOS)
TipRanks (Mon, 9-Nov 8:00 AM ET)
Zoetis Earnings Call: Resilience Meets Persistent Pet-Care Pressure
TipRanks (Sat, 7-Nov 7:15 PM ET)
UBS Sticks to Their Hold Rating for Zoetis (ZTS)
TipRanks (Fri, 6-Nov 10:07 AM ET)
TipRanks (Fri, 6-Nov 4:03 AM ET)
Zoetis beats top-line and bottom-line estimates; updates FY26 outlook
Seeking Alpha News (Thu, 5-Nov 7:04 AM ET)
Business Wire (Thu, 5-Nov 7:00 AM ET)
Business Wire (Tue, 20-Oct 4:42 PM ET)
Zoetis Appoints Iris Knobloch to its Board of Directors
Business Wire (Tue, 13-Oct 7:30 AM ET)
Zoetis Declares Fourth Quarter 2026 Dividend
Business Wire (Thu, 8-Oct 4:15 PM ET)
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns roughly 30% of total revenue from production animals (cattle, pigs, poultry, and so on) and nearly 70% from companion animal (dogs, horses, cats) products. Its US business is skewed even more heavily toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Zoetis Class A trades on the NYSE stock market under the symbol ZTS.
As of November 10, 2026, ZTS stock price declined to $81.56 with 76,242 million shares trading.
ZTS has a beta of 0.03, meaning it tends to be less sensitive to market movements. ZTS has a correlation of 0.00 to the broad based SPY ETF.
ZTS has a market cap of $33.70 billion. This is considered a Large Cap stock.
Last quarter Zoetis Class A reported $2 billion in Revenue and $1.75 earnings per share. This beat revenue expectation by $90 million and exceeded earnings estimates by $.24.
In the last 3 years, ZTS traded as high as $201.92 and as low as $68.77.
The top ETF exchange traded funds that ZTS belongs to (by Net Assets): VTI, VOO, VO, IVV, SPY.
ZTS has underperformed the market in the last year with a return of -30.4%, while SPY returned +12.8%. This shows that you would have done better investing in the overall market (through SPY) over the last year than in ZTS shares. However, ZTS has outperformed the market in the last 3 month and 2 week periods, returning +13.0% and +1.4%, while SPY returned -2.9% and -2.1%, respectively. This indicates ZTS has been having a stronger performance recently.
ZTS support price is $80.74 and resistance is $83.90 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ZTS shares will trade within this expected range on the day.
